Pharmacological interventions for hypertension in children

Evidence-Based Child Health

Volumn 9, Issue 3, 2014, Pages 498-580

  Chaturvedi, Swasti ^a   Lipszyc, Deborah H ^b   Licht, Christoph ^b   Craig, Jonathan C ^c   Parekh, Rulan ^b  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL SUCCINATE; OLMESARTAN; PLACEBO; POTASSIUM; TELMISARTAN; VALSARTAN;

ABDOMINAL PAIN; ACUTE ON CHRONIC RENAL FAILURE; ANGIONEUROTIC EDEMA; ANXIETY; ARM FRACTURE; ARTHRITIS; ASTHMA; BLOOD VESSEL OCCLUSION; BLURRED VISION; COMBINATION CHEMOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; FAINTNESS; FATIGUE; FOOT EDEMA; GASTROENTERITIS; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; HYPOKALEMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NIGHTMARE; PATIENT COMPLIANCE; PERICARDITIS; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SLEEP DISORDERED BREATHING; SORE THROAT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TOOTH PAIN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; VOMITING; XEROSTOMIA; ADOLESCENT; BLOOD PRESSURE; CHILD; CHILDHOOD OBESITY; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; PRESCHOOL CHILD; STROKE;

ADOLESCENT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PEDIATRIC OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 84927509224     PISSN: 20404050     EISSN: 15576272     Source Type: Journal    
DOI: 10.1002/ebch.1974     Document Type: Review

References (61)

1. Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, et al.Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. Journal of Pediatrics 2007;150(2):134-9.
2. Bristol-Meyers Squibb. United States Food and Drug Administration. Summaries of Medical and Clinical Pharmacology Reviews. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm161894.htm 2005.
3. Falkner B, Onesti G, Lowenthal DT, Affrime MB. Use of clonidine monotherapy (versus diuretics) in adolescent hypertension. Chest 1983;83:425-7.
4. Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al.A randomized, placebo-controlled trial of amlodipine in children with hypertension. Journal of Pediatrics 2004;145(3):353-9.
5. Flynn JT, Meyers KE, Neto JP, de Paula Meneses R, Zurowska A, Bagga A, et al.Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension 2008;52(2):222-8.
6. Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, et al.Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney International 2003;64(4):1450-4.
7. Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman RA, Assessment of Efficacy and Safety of Olmesartan in Pediatric Hypertension (AESOP) Study Group. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 2010;55(6):1323-30.
8. Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R, Assessment of Efficacy and Safety of Olmesartan in Pediatric Hypertension (AESOP) Study Group. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 2010;55(6):1323-30.
9. Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, et al.Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?. Hypertension 2004;44(3):289-93.
10. Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, Pressler ML. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. Journal of Pediatrics. United States: Division of Pediatric Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA. jennifer.li@duke.edu, 2010; Vol. 157, issue 2:282-7.
11. Schaefer F, Walle JVD, Zurowska A, Gimpel C, Hoeck KV, Drozdz D, et al for the Candesartan in Children with Hypertension (CINCH) Investigators. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. Journal of Hypertension 2010;28(5):1083-90.
12. Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, et al.Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. Journal of Hypertension 2011;29:2484-90.
13. Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al.A double-blind, dose-response study of losartan in hypertensive children. American Journal of Hypertension 2005;18(2 Pt 1):183-90.
14. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. American Journal of Hypertension 2003;16(10):795-800.
15. Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al.Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatric Nephrology 2002;17(5):345-50.
16. Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, et al.Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatric Nephrology 2003;18(6):548-53.
17. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J for the Candesartan in Children with Hypertension (CINCH) Investigators. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. Journal of Clinical Hypertension 2008;10(10):743-50.
18. Webb NJA, Lam C, Loeys T, Shahinfar S, Strehlau J, Wells TG, et al.Randomized, double-blind, controlled study of losartan in children with proteinuria. Clinical Journal of the American Society of Nephrology 2010;5:417-24.
19. Webb NJA, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, et al.An open-label dose-response study of losartan in hypertensive children. Pediatric Nephrology 2013;28(8):1636.
20. Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al.A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. Journal of Clinical Pharmacology 2002;42(8):870-80.
21. Wells TG, Portman R, Norman P, Haertter S, Davidai G, Fei Wang. Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension. Clinical Pediatrics 2010;49(10):938-46. [PUBMED: 20724342]
22. Wells T, Blumer J, Meyers KE, Neto JP, Meneses R, Litwin M, et al.Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. Journal of Clinical Hypertension 2011;13(5):357-65.
23. Bachmann H. Propranolol versus chlorthalidone--a prospective therapeutic trial in children with chronic hypertension. Helvetica Paediatrica Acta 1984;39(1):55-61.
24. Berenson GS, Shear CL, Chiang YK, Webber LS, Voors AW. Combined low-dose medication and primary intervention over a 30-month period for sustained high blood pressure in childhood. American Journal of the Medical Sciences 1990;299(2):79-86.
25. Chan EK, Quach J, Mensah FK, Sung V, Cheung M, Wake M. Dark chocolate for children's blood pressure: randomised trial. Archives of Disease in Childhood 2012;97:637-40.
26. Cichocka E, Januszewicz P, Wyszynska T. Evaluation of the efficacy and tolerance of three antihypertensive agents used as single-drug therapy, nifedipine, prazosin and acebutolol in severe, idiopathic hypertension in adolescents. Annales de Pediatrie 1993;40(2):119-26.
27. Ellis D, Moritz ML, Vats A, Janosky JE. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. American Journal of Hypertension 2004;17(10):928-35.
28. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008;300(8):924-32.
29. Friedman A, Chesney RW, Ball D, Goodfriend T. Effective use of captopril (angiotensin I-converting enzyme inhibitor) in severe childhood hypertension. Journal of Pediatrics 1980;97(4):664-7.
30. Meyers KEC, Lieberman K, Solar-Yohay S, Han G, Shi V. The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients. Journal of Clinical Hypertension 2011;13:758-66.
31. Moncica I, Oh PI, ul Qamar I, Scolnik D, Arbus GS, Hebert D, et al.A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Archives of Disease in Childhood 1995;73(2):154-6.
32. Morsi MR, Madina EH, Anglo AA, Soliman AT. Evaluation of captopril versus reserpine and frusemide in treating hypertensive children with acute post-streptococcal glomerulonephritis. Acta Paediatrica 1992;81(2):145-9.
33. Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatric Nephrology 2000;14(12):1083-7.
34. Sinaiko AR, Mirkin BL. Management of severe childhood hypertension with minoxidil: a controlled clinical study. Journal of Pediatrics 1977;91(1):138-42.
35. Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O'Dea RF. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. Journal of Pediatrics 1983;103(5):799-805.
36. White CT, Macpherson CF, Hurley RM, Matsell DG. Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatric Nephrology 2003;18(10):1038-43.
37. ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al.Strict blood-pressure control and progression of renal failure in children. New England Journal of Medicine 2009;361(17):1639-50.
38. ALLHAT 2002
39. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
40. Assadi F. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatric Cardiology 2007;28(1):27-33.
41. Benjamin DK Jr, Smith BP, Jadhav P, Gobburu VJ, Murphy DM, Hasselblad V, et al.Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension 2008;51(4):834-40.
42. Bovet P, Chiolero A, Madeleine G, Gabriel A, Stettler N. Marked increase in the prevalence of obesity in children of the Seychelles, a rapidly developing country, between 1998 and 2004. International Journal of Pediatric Obesity 2006;1(2):120-8.
43. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72.
44. Couch SC, Saelens BE, Levin L, Dart K, Falciglia G, Daniels SR. The efficacy of a clinic-based behavioral nutrition intervention emphasizing a DASH-type diet for adolescents with elevated blood pressure. Journal of Pediatrics 2008;152(4):494-501.
45. Daniels SR, Lipman MJ, Burke MJ, Loggie JM. The prevalence of retinal vascular abnormalities in children and adolescents with essential hypertension. American Journal of Ophthalmology 1991;111(2):205-8.
46. Denzer C, Reithofer E, Wabitsch M, Widhalm K. The outcome of childhood obesity management depends highly upon patient compliance. European Journal of Pediatrics 2004;163(2):99-104.
47. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation 2007;116(13):1488-96.
48. Flynn J. Management of hypertension in the young: role of antihypertensive medications. Journal of Cardiovascular Pharmacology 2011;58(2):111-20.
49. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, et al.Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
50. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al.Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.
51. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
52. Laird WP, Fixler DE. Left ventricular hypertrophy in adolescents with elevated blood pressure: assessment by chest roentgenography, electrocardiography, and echocardiography. Pediatrics 1981;67(2):255-9.
53. Lande MB, Carson NL, Roy J, Meagher CC. Effects of childhood primary hypertension on carotid intima media thickness: a matched controlled study. Hypertension 2006;48(1):40-4.
54. Liberman JN, Berger JE, Lewis M. Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among children and adolescents. Archives of Pediatrics and Adolescent Medicine 2009;163:357-64.
55. Lipszyc D, Parekh RS. Hypertension in children and adolescents - diagnostic challenges and management. US Nephrol 2011;6(2):110-5.
56. McNiece KL, Poffenbarger T.S, Turner JL, Franco KD, Sorof JM, Portman RJ. Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. Hypertension 2007;50(2):392-5.
57. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-76.
58. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295(13):1549-55.
59. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
60. Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics 2003;111(1):61-6.
61. Taddei S, Bruno RM, Ghiadoni L. The correct administration of antihypertensive drugs according to the principles of clinical pharmacology. American Journal of Cardiovascular Drugs 2011;11:13-20.